Article
Preliminary in vitro and in vivo investigation of a potent platelet derived growth factor receptor (PDGFR) family kinase inhibitor.
Bioorganic & medicinal chemistry letters - 1 Jun 2018
Wilson Elizabeth A, Russu Wade A, Shallal Hassan M
Abstract excerpt
Aberrant expression of wild-type and mutant forms of the platelet-derived growth factor receptor (PDGFR) family of receptor tyrosine kinases has been implicated in various oncologic indications such as leukemias, gliomas, and soft tissue sarcomas. Clinically used kinase inhibitors imatinib and sunitinib are potent inhibitors of wild-type PDGFR family members, but show reduced binding to mutant forms. Here we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.